ImmunityBio (IBRX) Common Equity (2016 - 2025)
Historic Common Equity for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$524.3 million.
- ImmunityBio's Common Equity rose 2954.24% to -$524.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.3 million, marking a year-over-year increase of 2954.24%. This contributed to the annual value of -$489.1 million for FY2024, which is 1667.65% up from last year.
- Per ImmunityBio's latest filing, its Common Equity stood at -$524.3 million for Q3 2025, which was up 2954.24% from -$570.7 million recorded in Q2 2025.
- Over the past 5 years, ImmunityBio's Common Equity peaked at -$158.6 million during Q2 2021, and registered a low of -$744.2 million during Q3 2024.
- For the 5-year period, ImmunityBio's Common Equity averaged around -$468.4 million, with its median value being -$489.1 million (2024).
- Per our database at Business Quant, ImmunityBio's Common Equity tumbled by 120289.31% in 2021 and then soared by 2954.24% in 2025.
- ImmunityBio's Common Equity (Quarter) stood at -$243.9 million in 2021, then plummeted by 84.42% to -$449.8 million in 2022, then plummeted by 30.49% to -$587.0 million in 2023, then increased by 16.68% to -$489.1 million in 2024, then fell by 7.2% to -$524.3 million in 2025.
- Its Common Equity stands at -$524.3 million for Q3 2025, versus -$570.7 million for Q2 2025 and -$591.4 million for Q1 2025.